Mechanism of action and resistance to monoclonal antibody therapy |
| |
Authors: | Villamor Neus Montserrat Emili Colomer Dolors |
| |
Affiliation: | Unitat d'Hematopatologia, Hospital Clínic, Barcelona, Spain. |
| |
Abstract: | Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with hematological malignancies and autoimmune diseases. The most commonly employed humanized and chimeric MoAbs are rituximab, alemtuzumab (Campath-1H, Ilex Pharmaceuticals, San Antonio, TX), and gemtuzumab-ozogamicin (Mylotarg, Wyeth-Ayerst Laboratories, St Davids, PA). The mechanism of action of these antibodies, and host and cellular factors influencing the response, are not completely known. Induction of apoptosis, antibody-dependent cell cytotoxicity (ADCC), and complement-mediated cell death (CDC) is the proposed mechanism of action of these antibodies. We review the current understanding of the mechanism of action of and resistance to these MoAbs. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|